**Question:** A 40-year-old man with a history of diabetes and presenting with symptoms of chronic myeloid leukemia (CML) is being evaluated. The laboratory findings and peripheral blood smear are provided. Bone marrow aspiration has also been done. Which of the following drugs is most likely the person is taking? -

A. Glibenclamide
B. Imatinib
C. Metformin
D. Rosiglitazone

**Core Concept:**

Diabetes mellitus is a group of disorders characterized by hyperglycemia, resulting from defects in insulin secretion, insulin action, or both. The patient's long-standing history of diabetes and the management of the disease with medications are indicative of chronic conditions, such as type 2 diabetes.

**Why the Correct Answer is Right:**

The patient has chronic myeloid leukemia (CML), which is a type of leukemia characterized by the presence of the Philadelphia chromosome. This chromosome translocation results in the production of an abnormal tyrosine kinase called BCR-ABL1, which drives the uncontrolled proliferation of hematopoietic stem cells leading to the development of CML.

The correct answer is **B. Imatinib** because it is a tyrosine kinase inhibitor (TKI) specifically targeting the BCR-ABL1 enzyme, which is the hallmark of CML. Imatinib is the standard first-line therapy for CML and is usually prescribed in the chronic phase of the disease, where the patient presents.

**Why the Other Options are Incorrect:**

**A. Glibenclamide:** This is a sulfonylurea used for type 2 diabetes mellitus, not CML. It works by increasing insulin secretion from pancreatic beta cells and is not effective in treating CML.

**D. Rosiglitazone:** This is a thiazolidinedione used for type 2 diabetes mellitus, not CML. It works by improving insulin sensitivity in peripheral tissues and is not relevant to treating CML.

**C. Metformin:** This is a biguanide used for type 2 diabetes mellitus, not CML. It works by reducing hepatic glucose production and improving insulin sensitivity and is not relevant to treating CML.

**Clinical Pearls:**

1. A correct diagnosis of CML requires a combination of clinical, laboratory, and cytogenetic investigations. These include a complete blood count (CBC), bone marrow aspiration and biopsy, and chromosome analysis (bone marrow karyotyping).
2. Tyrosine kinase inhibitors (TKIs) like Imatinib are the standard first-line therapy for chronic phase CML.
3. In chronic phase CML, the patient is usually asymptomatic or has mild symptoms like fatigue, weight loss, and mild anemia.

4. Imatinib is specifically targeted to the BCR-ABL1 tyrosine kinase, which is overactive in CML, leading to uncontrolled proliferation of myeloid cells and symptoms like abdominal pain, fatigue, and weight loss.

Please note that this explanation focuses on the correct diagnosis and treatment of CML using Imatinib, as well as the importance of TKIs and the role of BCR-ABL1 ty